Peripheral Edema News and Research

RSS
Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

FDA grants marketing approval for Elitek

FDA grants marketing approval for Elitek

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

FDA approves Amitiza for irritable bowel syndrome with constipation

FDA approves Amitiza for irritable bowel syndrome with constipation

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Study has important implications for African Americans who suffer from high blood pressure

Study has important implications for African Americans who suffer from high blood pressure

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.